FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912077025> ?p ?o ?g. }

• W2912077025 abstract "Reduced artemisinin susceptibility and artemisinin-based combination therapy (ACT)-resistance against Plasmodium falciparum and chloroquine (CQ)-resistant P. vivax malaria has been reported in Vietnam. Two therapeutic efficacy studies were conducted in Thuan Bac District (Ninh Thuan Province, Vietnam) in 2015 and 2016 to determine the extent of reduced artemisinin susceptibility and ACT resistant falciparum malaria, and CQ-resistant vivax malaria were present.Twenty-seven patients with falciparum malaria were randomized to receive artesunate alone (AS ~ 4 mg/kg/day) for 4 days followed by dihydroartemisinin (DHA) (2.2 mg/kg)-piperaquine (PPQ) (18 mg/kg) daily for 3 days or artemether (AM) (1.7 mg/kg)-lumefantrine (LUM) (12 mg/kg) twice daily for 3 days. Sixteen subjects with vivax malaria received CQ (total 25 mg/kg over 3 days). The therapeutic efficacy study for treating falciparum malaria was complemented with molecular analysis for artemisinin and piperaquine resistance, and in vitro drug susceptibility testing. Patient's drug exposure following both falciparum and vivax treatment studies was determined.Twenty-five of 27 patients treated with the artemisinin regimens completed the 42-day follow-up period. None had parasites present on day 3 after commencing treatment with no incidence of recrudescence (100% curative rate). One patient on AS + DHA-PPQ was lost to follow-up and one patient had Plasmodium falciparum and Plasmodium vivax infection on day 0 by PCR. Of the vivax patients, 15 of 16 completed CQ treatment and two had a recurrence of vivax malaria on day 28, a failure rate of 13.3% (2/15). No mutations in the Pfkelch-13 gene for artemisinin resistance or exo-E415G gene polymorphism and amplification in plasmepsins 2 and 3 for piperaquine resistance were observed. In vitro testing of patient's falciparum parasites indicated susceptibility (low IC50 nM values) to dihydroartemisinin, lumefantrine, piperaquine and pyronaridine. Patient's drug exposure to artesunate and lumefantrine was comparable to published data, however, blood CQ concentrations were lower.Clinical findings, molecular analysis and in vitro testing revealed that the falciparum parasites at Phuoc Chien Commune were artemisinin susceptible. The clinical failure rate of the 15 vivax patients who completed CQ treatment was 13%. Further studies are required to determine whether CQ-resistant vivax malaria is present at the commune." @default.
• W2912077025 created "2019-02-21" @default.
• W2912077025 creator A5001773072 @default.
• W2912077025 creator A5020608941 @default.
• W2912077025 creator A5024468785 @default.
• W2912077025 creator A5033601129 @default.
• W2912077025 creator A5044491731 @default.
• W2912077025 creator A5061505783 @default.
• W2912077025 creator A5072638559 @default.
• W2912077025 creator A5076590792 @default.
• W2912077025 creator A5077055573 @default.
• W2912077025 date "2019-01-17" @default.
• W2912077025 modified "2023-10-15" @default.
• W2912077025 title "Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam" @default.
• W2912077025 cites W1604979331 @default.
• W2912077025 cites W1749239895 @default.
• W2912077025 cites W1921967810 @default.
• W2912077025 cites W1951642591 @default.
• W2912077025 cites W1960873595 @default.
• W2912077025 cites W1993347313 @default.
• W2912077025 cites W2001645156 @default.
• W2912077025 cites W2014392076 @default.
• W2912077025 cites W2033755024 @default.
• W2912077025 cites W2042116011 @default.
• W2912077025 cites W2048267329 @default.
• W2912077025 cites W2056895566 @default.
• W2912077025 cites W2074438244 @default.
• W2912077025 cites W2088387917 @default.
• W2912077025 cites W2090726723 @default.
• W2912077025 cites W2094584642 @default.
• W2912077025 cites W2100666999 @default.
• W2912077025 cites W2105668259 @default.
• W2912077025 cites W2111658433 @default.
• W2912077025 cites W2112261944 @default.
• W2912077025 cites W2124634096 @default.
• W2912077025 cites W2129428401 @default.
• W2912077025 cites W2132107151 @default.
• W2912077025 cites W2139810119 @default.
• W2912077025 cites W2143838330 @default.
• W2912077025 cites W2144874346 @default.
• W2912077025 cites W2148068300 @default.
• W2912077025 cites W2149311205 @default.
• W2912077025 cites W2151292805 @default.
• W2912077025 cites W2159905542 @default.
• W2912077025 cites W2161311583 @default.
• W2912077025 cites W2166261288 @default.
• W2912077025 cites W2166746147 @default.
• W2912077025 cites W2167053896 @default.
• W2912077025 cites W2169511625 @default.
• W2912077025 cites W2187436842 @default.
• W2912077025 cites W2221909792 @default.
• W2912077025 cites W2328008522 @default.
• W2912077025 cites W2339928466 @default.
• W2912077025 cites W2401730911 @default.
• W2912077025 cites W2414906024 @default.
• W2912077025 cites W2432984814 @default.
• W2912077025 cites W2547042202 @default.
• W2912077025 cites W2547295550 @default.
• W2912077025 cites W2579721738 @default.
• W2912077025 cites W2775427409 @default.
• W2912077025 cites W2803728253 @default.
• W2912077025 cites W2950531058 @default.
• W2912077025 doi "https://doi.org/10.1186/s12936-019-2640-2" @default.
• W2912077025 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6335800" @default.
• W2912077025 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30654808" @default.
• W2912077025 hasPublicationYear "2019" @default.
• W2912077025 type Work @default.
• W2912077025 sameAs 2912077025 @default.
• W2912077025 citedByCount "11" @default.
• W2912077025 countsByYear W29120770252020 @default.
• W2912077025 countsByYear W29120770252021 @default.
• W2912077025 countsByYear W29120770252022 @default.
• W2912077025 countsByYear W29120770252023 @default.
• W2912077025 crossrefType "journal-article" @default.
• W2912077025 hasAuthorship W2912077025A5001773072 @default.
• W2912077025 hasAuthorship W2912077025A5020608941 @default.
• W2912077025 hasAuthorship W2912077025A5024468785 @default.
• W2912077025 hasAuthorship W2912077025A5033601129 @default.
• W2912077025 hasAuthorship W2912077025A5044491731 @default.
• W2912077025 hasAuthorship W2912077025A5061505783 @default.
• W2912077025 hasAuthorship W2912077025A5072638559 @default.
• W2912077025 hasAuthorship W2912077025A5076590792 @default.
• W2912077025 hasAuthorship W2912077025A5077055573 @default.
• W2912077025 hasBestOaLocation W29120770251 @default.
• W2912077025 hasConcept C126322002 @default.
• W2912077025 hasConcept C159047783 @default.
• W2912077025 hasConcept C203014093 @default.
• W2912077025 hasConcept C2776120307 @default.
• W2912077025 hasConcept C2777616469 @default.
• W2912077025 hasConcept C2778048844 @default.
• W2912077025 hasConcept C2778059366 @default.
• W2912077025 hasConcept C2778118209 @default.
• W2912077025 hasConcept C2778371730 @default.
• W2912077025 hasConcept C2779997623 @default.
• W2912077025 hasConcept C2780780316 @default.
• W2912077025 hasConcept C2781160685 @default.
• W2912077025 hasConcept C71924100 @default.
• W2912077025 hasConcept C86803240 @default.
• W2912077025 hasConcept C98274493 @default.
• W2912077025 hasConceptScore W2912077025C126322002 @default.

• next